FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study

Karen Juul Mylam, Lale Kostakoglu, Martin Hutchings, Morton Coleman, Dominic Lamonica, Myron S Czuczman, Louis F Diehl, Anne L Nielsen, Paw Jensen, Annika Loft, Helle W Hendel, Victor Iyer, Sirpa Leppä, Sirkku Jyrkkiö, Harald Holte, Mikael Eriksson, Dorte Gillstrøm, Per B Hansen, Marko Seppänen, Karin HjorthaugPeter de Nully Brown, Lars M Pedersen

24 Citationer (Scopus)

Abstract

ABSTRACT We evaluated the predictive value of I-PET after one course of chemoimmunotherapy in patients with newly diagnosed DLBCL. 112 DLBCL patients were enrolled. All patients had PET/CT scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International harmonization project criteria (IHP) and to Deauville 5 point scale (D 5PS) with scores 1-3 considered negative (D 5PS>3) and D 5PS with scores 1-4 considered negative (D5PS=5). Ratios of tumorSUVmax to liverSUVmax were also analyzed. We found no difference in progression-free survivals (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS>3. The 2-year PFS using D 5PS=5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p=0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish a D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET positive and PET negative patients in different prognostic groups.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind56
Udgave nummer7
Sider (fra-til)2005-12
ISSN1042-8194
DOI
StatusUdgivet - 2015

Fingeraftryk

Dyk ned i forskningsemnerne om 'FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study'. Sammen danner de et unikt fingeraftryk.

Citationsformater